What is Canbridge Pharmaceuticals Debt-to-EBITDA?
Debt-to-EBITDA measures a company's ability to pay off its debt.
Canbridge Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$38.0 Mil. Canbridge Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$117.3 Mil. Canbridge Pharmaceuticals's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-309.3 Mil.
Canbridge Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.50.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Canbridge Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
HKSE:01228'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.42 Med: -0.33 Max: -0.05
Current: -0.42
During the past 5 years, the highest Debt-to-EBITDA Ratio of Canbridge Pharmaceuticals was -0.05. The lowest was -0.42. And the median was -0.33.
Canbridge Pharmaceuticals Debt-to-EBITDA Historical Data
The historical data trend for Canbridge Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canbridge Pharmaceuticals Debt-to-EBITDA Chart
|
Canbridge Pharmaceuticals Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-EBITDA |
|
-0.33 |
-0.06 |
-0.05 |
-0.34 |
-0.42 |
|
Canbridge Pharmaceuticals Semi-Annual Data
|
|
Dec19 |
Jun20 |
Dec20 |
Jun21 |
Dec21 |
Jun22 |
Dec22 |
Jun23 |
Dec23 |
| Debt-to-EBITDA |
Get a 7-Day Free Trial
|
|
-0.04 |
-0.33 |
-0.36 |
-0.38 |
-0.50 |
Competitive Comparison of Canbridge Pharmaceuticals's Debt-to-EBITDA
For the Biotechnology subindustry, Canbridge Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals's Debt-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's Debt-to-EBITDA falls into.
Canbridge Pharmaceuticals Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
Canbridge Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Canbridge Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.
Canbridge Pharmaceuticals (HKSE:01228) Business Description
Traded in Other Exchanges
Address
Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park,, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Executives
Canbridge Pharmaceuticals (HKSE:01228) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01228 has been successfully added to your